A hallmark of HIV-1 infection in vivo is systemic chronic immune activation 1 , which has been postulated to lead to HIV-associated non-AIDS complications (HANA) 2 and dysfunction of T cells 3 . Despite long-term viral suppression by cART and restoration of CD4 + T-cell levels, immune activation, and inflammation persist in the majority of treated HIV-infected individuals, and is associated with excess risk of mortality and morbidity. Many factors have been attributed to cause this aberrant immune activation in vivo, such as bacterial endotoxin or co-infections 4 ; however, a viral (HIV) etiology for the chronic inflammatory state has remained unclear. Persistent infection of myeloid cells, most likely tissue-resident macrophages, is postulated to contribute to chronic immune activation and HANAs [5] [6] [7] , though molecular mechanisms of how HIV-1 replication activates macrophages remain poorly understood.
In this study, we report that expression and Rev-CRM1dependent nuclear export of intron-containing HIV-1 RNA (icRNA) activates host sensing mechanisms and type I interferon (IFN-I)-dependent pro-inflammatory responses via MAVS in productively infected macrophages. Additionally, the ability of cells to distinguish intron-containing HIV-1 RNA from self mRNA is dependent on the localization of non-self HIV icRNA at peripheral membrane sites. Interestingly, HIV-1 infection-induced activation of macrophages, in turn, leads to upregulation of inhibitory receptor (IR) expression and reduced effector function of co-cultured autologous CD4 + and CD8 + T cells, and the phenotype is suppressed upon antagonism of IFN-I. These findings suggest that novel therapeutic strategies that suppress viral icRNA expression and IFN-I signaling cascades in tissue macrophages might have immunologic and therapeutic benefit in HIV-1 infected individuals on cART.
Results
Late step of HIV replication triggers MDM immune activation.
HIV-1 infection of monocyte-derived macrophages (MDMs) results in induction of a myeloid cell specific ISG, CD169/Siglec1 ( Fig. 1a and Supplementary Fig. 1a ) 8 whose expression is dramatically upregulated (fivefold) even upon low levels (<0.3 U ml -1 ) of IFN-α exposure ( Supplementary Fig. 1b ) in both infected and uninfected bystander MDMs. Interestingly, enhancement of CD169 expression ( Fig. 1b and Supplementary  Fig. 1c ) on MDMs and secretion of pro-inflammatory cytokines, IP-10 (CXCL10) (Fig. 1c) , IFN-α2, MCP-1, IL-15, and VEGF ( Supplementary Fig. 1d -g) were abrogated upon pre-treatment with inhibitors of HIV-1 fusion (maraviroc), RT (AZT), integration (raltegravir) or p-TEFβ-mediated (i.e., Tat Fig. 1 Late step of HIV-1 replication in macrophages triggers immune activation. a Flow cytometry profiles (CD169 expression and intracellular p24 Gag ) of MDMs 6 days post infection with replication competent HIV-1 at MOI of 1. b, c Effects of HIV-1 inhibitors on CD169 expression (b) and IP-10 production (c) in MDMs. MDMs were treated with drugs prior to infection (maraviroc, AZT or raltegravir) or post infection (flavopiridol and indinavir) with replication competent HIV-1 as described in a. d Temporal expression of IFN-β mRNA in MDMs. MDMs were infected with a single-round HIV-1 (LaiΔenvGFP/G) at MOI of 2 and cells were harvested on day 1, 2, and 3 post infection for mRNA extraction. e-g Effect of B18R on CD169 expression (e), IP-10 production (f), and HIV-1 infection (g) in MDMs. MDMs were infected with replication competent HIV-1 as in a and analyzed 6 days post infection. NT: untreated. The means ± SEM are shown and each symbol represents an independent experiment. Two-tailed p-values: one-way ANOVA followed by the Tukey-Kramer post-test (e, f) or the Dunnett's post-test (b, c, and d) or paired t-test (g), *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant transcription (flavopiridol) but not upon treatment with a protease inhibitor (indinavir) ( Supplementary Fig. 1h ), suggesting that a post-transcriptional step in HIV-1 replication cycle activates MDMs. Furthermore, induction of IFN-β mRNA expression in productively infected MDMs was detected at 3 days post infection ( Fig. 1d ), which was coincident with the upregulation of CD169 and other ISGs ( Supplementary Fig. 1i , j), further supporting the hypothesis that a late event in the virus replication cycle induces IFN-I responses. Moreover, B18R, IFN-I neutralizing reagent, potently inhibited CD169 expression on infected and bystander MDMs ( Fig. 1e and Supplementary Fig. 1k ) and reduced IP-10 secretion (Fig. 1f) , while, co-infection of vesicular stomatitis virus (VSV, whose infection is highly sensitive to IFN-I 9 ) was inhibited in HIV-1-infected MDMs ( Supplementary Fig. 1l, m) , confirming the presence of bioactive IFN-I in the HIV-1-infected MDM culture supernatants. However, the levels of secreted IFN-I were below the detection limit of a conventional bioassay (Supplementary Fig. 1n ) and had negligible impact on HIV-1 infection (spread) ( Fig. 1g and Supplementary Fig. 1o ). Collectively, these results suggest that host sensing of a late step of HIV-1 replication in MDMs induces IFN-I-dependent pro-inflammatory responses.
HIV structural and accessory proteins do not activate MDM. Although induction of pro-inflammatory responses has been described upon exposure to HIV-1 accessory or structural proteins in diverse cell types 10, 11 , MDMs infected with Nef, Env, Vpu, Vpr, or Vif-deficient mutants ( Fig. 2a ) displayed robust induction of CD169 and IP-10 expression ( Fig. 2b , c and Supplementary Fig. 2a ). Moreover, MDM infections with Gag p6 (Δp6), NC (ΔNCp6), MA (ΔMA) truncation mutants, or Gag start codon mutant (ATG*) ( Fig. 2d , e, h) that results in initiation of Gag translation from an in-frame internal ATG present at the N-terminus of CA (leading to expression of aberrant Gag; Supplementary Fig. 2b ) failed to abrogate CD169 or IP-10 induction ( Fig. 2f , g, i, j). Additionally, infection of MDMs with HIV-1 budding-deficient mutant (PTAP-) 12 , CA-mutants deficient for Gag-Gag interaction 13 , and cyclophilin A (CyPA)-binding-deficient CA mutant G89V ( Supplementary Fig. 2c , f, i) resulted in upregulation of CD169 and IP-10 ( Supplementary Fig. 2d , e, g, h, j, k), suggesting that neither virion-release 14 , cytoplasmic accumulation of higher-ordered Gag assembly intermediates nor CyPA-binding to de novo expressed Gag, a target of a cryptic sensor in myeloid dendritic cells 11 , is required for MDM activation. Furthermore, complete abrogation of Gag-pol expression (ΔGag-pol; Fig. 2d and Supplementary Fig. 2b ) only modestly attenuated expression of CD169 and IP-10 ( Fig. 2l , m) in infected MDMs ( Fig. 2k ), suggesting that structural and accessory proteins of HIV-1 do not encode immune-activation determinants.
CRM1-dependent HIV icRNA export is sensed in myeloid cells.
To identify the post-transcriptional viral product that induces pro-inflammatory responses in MDM, we next assessed the effect of viral RNA on MDM activation. There are three classes of viral mRNAs (multiply-spliced, singly-spliced, and unspliced) transcribed from the HIV-1 LTR 15 . Nuclear export of HIV-1 icRNA relies on Rev-RRE binding and a cellular mRNA transporter CRM1 16, 17 . Mutations that disrupt Rev binding to CRM1 (M10 mutant; Supplementary Fig. 3a ) or delete RRE (ΔRRE; Supplementary Fig. 3a ), abrogate icRNA nuclear export and thus Gag expression, but not export and translation of multiply-spliced viral RNAs (i.e., GFP in place of nef; Fig. 3a, b and Supplementary  Fig. 3b ) 16, 17 . Interestingly, infection of MDMs with the M10 mutant failed to upregulate CD169 and IP-10 expression ( Fig. 3c,  d ). Insertion of the constitutive transporting element (CTE) from Mason-Pfizer monkey virus (MPMV) 18 within the pol open reading frame (orf) of the M10 mutant (M10 -CTE) or the ΔRRE mutant (ΔRRE-CTE) in the sense orientation, but not in the antisense orientation (M10-CTE-AS), rescued nuclear export of HIV-1 icRNA and Gag expression ( Fig. 3a and Supplementary Fig. 3a , b). However, the rescue of HIV-1 icRNA nuclear export by CTEdependent pathway failed to induce CD169 or IP-10 expression ( Fig. 3c, d ). Moreover, while Rev-dependent expression of a nonviral protein (TagRFP) from the intron-containing viral RNA ( Fig. 3e , f) induced CD169 and IP-10 expression ( Fig. 3g, h and Supplementary Fig. 3c, d ), Rev-independent expression of a nonviral protein (ZsGreen) ( Fig. 3e , i) from an intron-less mRNA from a lentivector failed to induce CD169 and IP-10 expression ( Fig. 3j , k and Supplementary Fig. 3e ). A potent CRM1 inhibitor KPT-330 (Selinexor), which prevented icRNA-encoded Gag expression but not multiply-spliced-RNA-encoded GFP (in place of nef) expression ( Fig. 3l and Supplementary Fig. 3f ), potently inhibited upregulation of CD169 ( Fig. 3m and Supplementary  Fig. 3g ) and IP-10 ( Fig. 3n ), further supporting the importance of Rev-CRM1 pathway in MDM activation. Myeloid dendritic cells can play an important role in mucosal transmission and systemic dissemination of HIV-1 19, 20 . Establishment of productive HIV-1 infection in monocyte-derived dendritic cells (MDDCs) also upregulated CD169 (Fig. 3o ), and the activation was suppressed by efavirenz (EFZ, an RT inhibitor), raltegravir (Ral) and KPT-330 ( Fig. 3p, q and Supplementary  Fig. 3h ). However, CD169 expression was not induced in MDDCs by lentivector-driven expression of ZsGreen even at high level of infection (Fig. 3r, s and Supplementary Fig. 3i ), phenocopying our findings in MDMs. Collectively, these findings suggest that engagement of divergent RNA nuclear export pathways such as those mediated by Rev-RRE and MPMV CTE might lead to altered exposure of viral icRNA to host cytoplasmic sensing machinery, and that host sensing of viral icRNA specifically exported via Rev-CRM1-dependent pathway is necessary for inducing pro-inflammatory responses in myeloid cells such as MDMs and MDDCs.
Membrane targeting of HIV icRNA is the trigger for sensing. HIV-1 icRNA exported via Rev-RRE or CTE-dependent pathway results in distinct cytoplasmic distribution 21 . We, therefore, tested the hypothesis that cytoplasmic localization of HIV-1 icRNAassociated ribonucleoprotein complexes (RNPs) specific to the Rev-RRE pathway dictates induction of pro-inflammatory signaling cascades. Since a subset of cytoplasmic HIV-1 icRNAs are trafficked to membrane-associated virus assembly sites for association with Gag and packaging into new virions 13, 15 , we infected MDMs with a series of Gag mutants to potentially modulate localization of HIV-1 icRNA-associated RNPs ( Fig. 4a and Supplementary Fig. 4a ). Interestingly, infection of MDMs with myristoylation-deficient MA mutant (G2A) that prevents stable membrane association of HIV-1 Gag 13 attenuated viral icRNAinduced MDM activation (Fig. 4b, c ), while none of the other well-characterized MA membrane-targeting domain mutants or those that potentially alter Gag assembly structure or icRNA-Gag association prevented MDM activation ( Supplementary Fig. 4b , c). Membrane-targeting function is well conserved among all retroviral MA proteins, though site of virus assembly varies among retroviruses 15 . To putatively alter membrane association sites of HIV-1 icRNA, we introduced diverse lentiviral and retroviral MA sequences in place of HIV-1 MA, including MLV-MA ( Fig. 4d ). The MLV/HIV chimeric constructs contained the first 42 nucleotides of the HIV-1 gag orf followed by the start codon for MLV-MA in order to facilitate optimal incorporation of chimeric viral genome into HIV-1 particles 22 . This additional HIV-1 sequence either contained a point mutation to disrupt the translational initiation codon for HIV-1 Gag sequence such that the chimeric MLV/HIV-1 Gag polyprotein contains no HIV-1 MA residues (mMA, Supplementary Fig. 4d ) or retained the intact ATG that leads to translation of a chimeric fusion protein from the intact HIV-1 Gag start codon (mMA-fusion contains the first 14 amino-acid residues of HIV-1 MA, Supplementary  Fig. 4d ) 22 . Transduction of MDMs with the chimeric MLV/HIV MA viruses revealed that establishment of productive infection with mMA chimeric virus ( Fig. 4e ) did not induce CD169 or IP-10 production ( Fig. 4f, g ). Furthermore, complete replacement of the HIV-1 MA with MA and p12 of MLV ( Supplementary  Fig. 4e ), such that the chimeric Gag polyprotein contains no HIV-1 MA sequences 23 , attenuated CD169 and IP-10 expression in productively infected MDMs ( Supplementary Fig. 4f -h). In contrast, transduction of MDM with mMA-fusion chimeric virus induced CD169 and IP-10 expression ( Fig. 4f, g) . Interestingly, MLV-MA-chimeric HIV was unique in its inability to activate MDMs, since infection of MDMs with lentiviruses encoding chimeric Gag with MA sequences derived from other lentiviruses (HIV-2, SIV mac , SIV agm , SIV cpz , SIV gor , FIV or EIAV) or deltaretrovirus (HTLVII) ( Supplementary Fig. 4i , l) upregulated CD169 and IP-10 expression ( Supplementary Fig. 4j , k, m, n). While Gag (p24 CA ) production in mMA and mMA-fusion virus-transduced MDMs was similar to that observed upon infection with wild type HIV-1 ( Fig. 4h ), mMA virus particles released from MDMs and HeLa cells contained significantly fewer copies of viral genomic RNA compared to HIV-1 (wild type) or mMA-fusion virus particles ( Fig. 4i , j), indicative of differential icRNA-Gag association among the three viruses. To investigate localization of viral icRNA in MLV/HIV chimeric Gag expressing cells, viruses were constructed that contained 24 copies of the RNA MS2binding stem loops in the pol orf and encoded a nuclear localized-GFP-bacterial phage MS2 coat fusion protein (MS2-GFP-NLS) located within the nef orf ( Supplementary Fig. 4o ). Since the MS2 stem loops are located in the pol orf, only the viral icRNA could be bound and labeled by MS2-GFP proteins (Supplementary Fig. 4o ) 24 . We found that while HIV-1 Gag strongly colocalized with the viral icRNA at Gag assembly sites, mMA icRNA and mMA Gag did not co-localize ( Fig. 4k, l) . Interestingly, co-localization of viral icRNA and Gag was restored in mMA-fusion-expressing cells, though at membrane sites distinct from those observed with wild type HIV-1 (Fig. 4k, l) . These results suggest that stable membrane association of viral icRNA is necessary for host sensing and induction of type I IFN-dependent pro-inflammatory signals in MDMs.
MDM activation is initiated via a MAVS-dependent pathway. Cytosolic HIV-1-derived nucleic acids can be sensed and trigger induction of innate immune responses via MAVS and/or STING 25 . To identify the signaling pathways induced upon sensing of HIV-1 icRNA, MDMs were transduced with lentivectors expressing shRNA against MAVS or STING ( Fig. 5a and Supplementary Fig. 5a ). While infection of MDMs containing shRNA against MAVS or STING did not affect subsequent HIV-1 (Fig. 5b, c and Supplementary Fig. 5b, c) , intriguingly, induction of CD169 expression on MDMs was not observed in the absence of MAVS ( Fig. 5d and Supplementary Fig. 5b ). In contrast, knockdown of STING expression had a negligible impact on upregulation of CD169 upon HIV-1 infection ( Fig. 5e and Supplementary Fig. 5c ). Since RIG-I and MDA5 are cellintrinsic viral nucleic acid sensors that detect cytosolic viral RNAs and trigger MAVS-dependent signaling events 26 , we next investigated whether sensing of HIV-1 icRNA was initiated by RIG-I and MDA5. Knockdown of RIG-I and MDA5 ( Fig. 5f and Supplementary Fig. 5a ) affected neither susceptibility to HIV-1 infection (Fig. 5g, h and Supplementary Fig. 5d , e) nor enhancement of CD169 expression upon HIV-1 infection in MDMs (Fig. 5i, j and Supplementary Fig. 5d, e) , implying there is a yet-to-be identified RNA sensor detecting HIV-1 icRNA.
Since MAVS is thought to provide a mitochondrial membraneassociated scaffold for transducing signaling cascades downstream of numerous pathogen sensing mechanisms 26 , we sought to identify the signaling pathways that activate MAVS and/or are activated via MAVS upon sensing of HIV-1 icRNA. MDMs were infected with single cycle HIV-1 and treated with inhibitors targeting molecules involved in signaling upon pathogen sensing: TAK1
((5Z)-7-Oxozeaenol) 14 , NF-κB (BAY11-7082) 14 , Ca 2+ -dependent signaling pathway (calpeptin) 27 , NLRP3 inflammasome (glybenclamide) 28 , and herbimycin A, an inhibitor of non-receptor tyrosine kinases including c-Abl, which is involved in MAVS activation 29 . None of the inhibitors were cytotoxic ( Supplementary Fig. 5f ), and they had negligible effects on HIV-1 infection ( Fig. 5k and Supplementary Fig. 5g ), Gag expression ( Supplementary Fig. 5h ), or virus particle release ( Supplementary  Fig. 5i ). We observed that CD169 expression and IP-10 secretion were reduced in infected MDMs upon blocking TAK1 or NF-κB activation and most potently blocked by herbimycin A (Fig. 5l, m and Supplementary Fig. 5g ). These results suggest that TAK1, NF-κB, and non-receptor tyrosine kinases are likely involved in MDM activation induced upon host sensing of de novo expressed HIV-1 icRNA.
HIV-induced MDM activation results in T-cell exhaustion. In chronic viral infections such as HIV-1 in humans and lymphocytic choriomeningitis virus (LCMV) in mice, chronic immune activation can result in T-cell exhaustion 3 . Therefore, we sought to determine the effect of MDM immune activation induced by HIV-1 infection on functional capacity of T cells. HIV-1-infected MDMs were co-cultured with autologous CD14-depleted PBMCs, Fig. 6a and Supplementary Fig. 6a ). Interestingly, co-culture of HIV-1-infected MDMs and PBMCs upregulated expression of PD-1, CD160, and Lag-3 on CD4 + and CD8 + T cells ( Fig. 6b-e ). While Lag-3 expression was transiently enhanced on CD8 + T cells (Fig. 6b, c) , CD160 expression was upregulated on CD4 + and CD8 + T cells at both 2 and 5 days post initiation of co-culture ( Fig. 6b-e ). CD160 expression has been shown to correlate with HIV-1 disease progression and functional impairment of T cells 30, 31 . Indeed, we observed increased numbers of CD160 + PD-1 + CD8 + T cells ( Fig. 6f ) and CD160 + CD4 + T cells (Fig. 6g ) in co-cultures with HIV-infected MDMs, which was not observed when HIV-1 infection in MDMs was inhibited (AZT), soluble IFN-I was neutralized (B18R), or when MDMs were infected with HIV-1/ Rev-M10 mutant, which displays a block to HIV-1 icRNA nuclear export (M10). These T-cell exhaustion phenotypes were also seen when co-cultures were initiated with fewer numbers of HIVinfected MDMs (1% GFP + cells at MOI of 0.02) ( Supplementary  Fig. 6b-d ). Finally, we examined functionality of the IR + T cells by performing intracellular cytokine staining for IFN-γ production upon T-cell stimulation with SEB. Intriguingly, we observed a significant decrease in the frequency of IFN-γ producing cells in the CD160 + PD-1 + double-positive CD8 + T-cell population ARTICLE compared to CD160 − PD-1double-negative CD8 + T cells (Fig. 6h ). Furthermore, a similar decrease in IFN-γ producing cells was observed in CD160 + CD4 + T cells (Fig. 6i ), suggesting that exposure of CD8 + and CD4 + T cells to HIV-infected MDMs leads to upregulation of IR expression and functional impairment.
Discussion
Whether HIV-1 infection of MDMs is subject to sensing has remained a matter of controversy. In this study, we show that a late step of HIV-1 replication, specifically, expression and Rev-CRM1-mediated nuclear export of viral icRNA to membrane-associated virus particle assembly sites in MDMs is subject to MAVS-dependent host sensing mechanisms and results in induction of pro-inflammatory responses and innate immune activation. Importantly, Rev-CRM1-dependent nuclear export specifically marks HIV-1 icRNA for detection by cytoplasmic sensing mechanisms, since access to alternative CTE-dependent nuclear export pathway failed to induce pro-inflammatory responses. There seems to be no sequence specificity for the sensing mechanism since inclusion of non-viral sequences (TagRFP) in HIV icRNA failed to abrogate production of pro-inflammatory responses. While the distinct trafficking pattern and composition of viral icRNA-containing RNPs has been hypothesized to confer translational advantage to HIV-1 mRNAs compared to bulk host mRNA 32 , such differences might also subject viral icRNA to detection by host innate immune sensing mechanisms. It has been shown in neuronal cells that RNA-transporting granules (known as neuronal RNA granules) are trafficked to the vicinity of peripheral membrane sites distant from nucleus, and interestingly many of their components have also been found in HIV-1 RNP trafficking granules 33 . We speculate that HIV-1 icRNA-containing RNPs are by default trafficked to the vicinity of peripheral membrane, and that tethering of HIV-1 icRNA to distinct peripheral membrane sites appeared to be a critical determinant for induction of innate immune sensing. Expression of mutant Gag that alters intrinsic peripheral membrane localization of icRNA (MLV-MA) or by preventing stable membrane association (HIV-1 MA-G2A mutant) abrogated sensing and/or induction of IFN-I responses. Although MAVS requirement for HIV-1-induced MDM activation has been postulated before 34 , viral determinant that was subject to sensing has remained unclear. Here, we identify that Rev-CRM1-dependent icRNA export pathway triggers MAVS-dependent innate immune sensing by a yet-to-be identified sensor that resides at or in the vicinity of HIV-1 Gag assembly site. Further studies are warranted to elucidate HIV-1 icRNA trafficking mechanisms in MDMs, and to identify the cytosolic sensor of HIV-1 icRNA in MDMs. Expression of several viral proteins, including Gag, Tat and gp120 has been reported to activate myeloid cells including DCs, microglia, and macrophages. For instance, newly synthesized Gag is thought to activate DCs in a cell-intrinsic manner 11 , though results described in this report do not support the existence of a cryptic Gag protein sensor in myeloid cells. Furthermore, previous studies have reported that secreted viral proteins such as gp120 and Tat can cause microglia activation 35 . Differences in experimental system such as target cells and methods to express viral proteins (infections in the presence of SIV mac Vpx to degrade SAMHD1 or transient overexpression) might account for the discrepant findings.
MDM sensing of HIV-1 icRNA expression resulted in low levels of IFN-I production that had negligible effects on virus replication, though the establishment of a IFN-I-dependent chronic inflammatory state might have detrimental consequences to the host. Here, we show that HIV-1-infectioninduced MDM activation led to the upregulation of IRs on cocultured T cells and functional impairment of IR + T cells. Importantly, the observed exhaustion phenotype of T cells was driven by IFN-I since the soluble IFN-I antagonist, B18R, abrogated the upregulation of IR expression on T cells, in agreement with recent in vivo findings on HIV-1 36, 37 and LCMV 38, 39 . Tissue-resident macrophages are important cellular targets of HIV and can remain persistently infected with HIV-1 even in individuals on cART [5] [6] [7] , and HIV-1 icRNAs have been detected in CD4 + T cells and alveolar macrophages from patients on longterm cART 40, 41 . A recent study quantified a number of SIV RNA expressing cells in non-human primates on cART and revealed that 98% of those cells were found in gut tissues 42 . While most of the SIV RNA + cells are presumably CD4 + T cells, previous estimates suggest myeloid cells including macrophages constitute up to~35% of total CD45 + cells in gut tissues 43 . Although expression of viral RNAs might not lead to functional viral protein production, persistent expression of viral icRNA might trigger chronic innate immune activation in MDMs, that we demonstrate is a potent stimulus of IFN-I-dependent proinflammatory responses, contributing to T-cell exhaustion and dysfunction. Although a vast majority of proviruses in HIV + individuals on cART are defective containing large internal deletions and/or APOBEC3G-mediated hypermutations 40, 44 , these defective HIV proviruses remain transcriptionally competent encoding non-functional proteins 40 . Future studies will need to investigate whether icRNA expression in myeloid cells is correlated with IR expression in T cells in tissues of HIV/SIVinfected individuals on cART. Unfortunately, current cART regimen does not block virus RNA transcription in previously infected cells. Thus, the development and clinical application of inhibitors that decrease viral RNA expression such as Tat and Rev inhibitors 45, 46 , especially in tissue macrophages, could alleviate systemic immune activation in HIV-infected individuals on cART.
Methods co-transfection of HIV-1Δenv constructs and VSV-G expression plasmid. To express HIV-1 mutants which by themselves cannot infect MDMs, a mutant plasmid was co-transfected with the packaging construct (psPAX2) and a VSV-G expression vector into HEK293T 53 . Lentivector expressing ZsGreen or shRNA was also generated by co-transfecting HEK293T cells with psPAX2 and a VSV-G expression vector using calcium phosphate or TransIT-293 (Mirus). Viruscontaining cell supernatants were harvested 2 days post-transfection, cleared of cell debris by centrifugation (300 x g, 5 min), passed through 0.45 µm filters, and purified and concentrated by ultracentrifugation on a 20% sucrose cushion (24,000 rpm and 4°C for 2 h with a SW32Ti or SW28 rotor (Beckman Coulter)). The virus pellets were resuspended in PBS, aliquoted, and stored at −80°C until use. The capsid content of HIV-1 was determined by a p24 gag ELISA 53 and virus titer was measured on TZM-bl 55 shRNA-mediated knockdown. To knockdown expression of host proteins, MDMs were transduced with lentivectors expressing shRNA (pLKO.1, 400 ng p24 Gag content per 1 × 10 6 cells) in the presence of SIVmac Vpx-containing VLPs pseudotyped with VSV-G (SIV3 + /G) and polybrene (Millipore) by spinoculation as described above. After culturing for 2 days, MDMs were cultured for another 5-7 days in the presence of puromycin (3 µg ml -1 , GIBCO or InvivoGen) for selection before being used for infection or other experiments. Knockdown efficiency was quantified by qRT-PCR or western blotting. All the shRNA target sequences are listed in Supplementary Table 2 .
Immunoblot analysis. To assess expression of viral proteins (p24 and p17) or to validate knockdown of host proteins (MAVS, STING, RIG-I, and MDA5), cell lysates containing 20−30 µg total protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and the membranes were probed with the following antibodies: a mouse anti-p24 antibody (p24-2, Dr. Michael H. Malim, NIH AIDS Reagent Program, #6457, 1:5000) or a rabbit anti-p24 antibody (ImmunoDX, #1303, 1:1000), a rabbit anti-p17 polyclonal antibody (VU47, Dr. Paul Spearman and Dr. Lingmei Ding, NIH AIDS Reagent Program, #4811, 1:1000), a rabbit anti-MAVS polyclonal antibody (Thermo Fisher, #PA5-17256, 1:1000), a rabbit anti-STING polyclonal antibody (Cell Signaling, #13647, 1:1000), a mouse anti-RIG-I antibody (Enzo Life Sciences, #ALX-804-849-C100, 1:1500) or a rabbit anti-MDA5 antibody (Proteintech, #21775-1-AP, 1:1000). Then, the membranes were stained with secondary antibodies, a goat anti-mouse-IgG-DyLight 680 (Pierce, # 35518, 1:10,000) or a goat anti-rabbit-IgG-DyLight 800 (Pierce, # 35571, 1:10,000). As loading controls, actin was probed using a rabbit anti-actin antibody (SIGMA, # A2066, 1:5000) or a mouse anti-actin antibody (Thermo Fisher, #AM4302, 1:5000). Membranes were scanned with an Odessy scanner (Li-Cor). All uncropped images are shown in Supplementary Fig. 7 .
mRNA and viral RNA Quantification. Total mRNA was isolated from 1 × 10 6 cells using a kit (RNeasy kit, QIAGEN) and reverse-transcribed using oligo(dT) 20 primer (Superscript III, Invitrogen). Target mRNA was quantified using Maxima SYBR Green (Thermo Scientific) and normalized to GAPDH mRNA by the 2 -ΔΔC T method as described 49, 56 . As a positive control for IFN-β mRNA expression, MDMs were treated with 1 µg ml -1 LPS (InvivoGen) for 2 h. For virion-associated viral RNA quantification, viral RNA was isolated from 140 µl cell-free culture supernatants using Qiamp Viral RNA mini kit (QIAGEN) and reverse-transcribed using random hexamers (Superscript III, Invitrogen). Viral cDNA was then quantified using Maxima SYBR Green (Thermo Scientific) using pLaiΔenvGFP as standard. All the primers used for quantitative PCR are listed in the Supplementary  Table 3 .
Cytokine quantification. IP-10 in MDM culture supernatants was measured with a BD Human IP-10 ELISA Set (BD). Multiplex cytokine assay using a human cytokine 29-plex kit (Millipore) was performed using culture supernatants and was analyzed with a DropArray (Curiox Biosystems) and the MAGPIX System (Luminex). Bioactive IFN-I was measured by a bioassay using 293 ISRE-luc cell line (a gift from Drs. Junzhi Wang, National Institute for the Control of Pharmaceutical and Biological Products, China and Xuguang Li, University of Ottawa, Canada) 49 .
Flow cytometry. CD169 expression on MDMs was quantified by staining with Alexa647-conjugated mouse anti-human CD169 antibody (BioLegend, # 346006, 1:50) and analyzed with BD LSRII (BD). Geo mean fluorescence intensity (MFI) was calculated and normalized to that of uninfected (mock) MDMs. In some experiments, intracellular p24 was stained as described 49 using FITC-or RD1conjugated mouse anti-p24 monoclonal antibody (KC57, Coulter, # 6604665 or # 6604667, 1:25). For T-cell exhaustion assay, MDM-PBMC co-culture was harvested, stained with Zombie-NIR (BioLegend, #423105, 1:250) and a panel of makers designed for inhibitory receptor expression profiling 57 , and analyzed with FACS ARIA (BD). For intracellular IFN-γ staining, MDM-PBMC co-culture was unstimulated or stimulated with SEB (List Biological Laboratories) for 1 h, followed by culture with brefeldin A (BioLegend) for another 5 h, stained for inhibitory receptors as described above, fixed with FluoroFix Buffer (BioLegend), and stored in a staining buffer (2% NCS in PBS). Fixed cells were permeabilized with intracellular staining permeabilization wash buffer (BioLegend), stained with antihuman IFN-γ PE (BioLegend, # 506506, 1:200), and analyzed with FACS ARIA (BD). Data was analyzed with FlowJo software (FlowJo).
Imaging. HeLa cells seeded on coverslips were transfected with a plasmid containing 24xMS2 binding loops and MS2-GFP-NLS by lipofectamine 2000 (Invitrogen). Cells were washed and fixed 24 h post-transfection with 4% parafolmaldehyde, permeabilized with 0.1% TritonX100, and stained with mouse anti-p24 antibody (AG3.0, Dr. Jonathan Allan, NIH AIDS Reagent Program, # 4121, 1:250) followed by staining with Alexa594-conjugated anti-mouse-IgG antibody (Invitrogen, # A-11020, 1:200) and DAPI (Sigma). Cells were mounted on a slide glass with Fluoromount-G (Southern Biotech) and imaged with a confocal microscopy (Leica SP5). For co-localization analysis, more than 50 cells were imaged, and correlation between p24 signals and GFP signals in cytosol (DAPI negative) were analyzed with ImageJ (NIH).
Statistics. All the statistics analysis was performed using GraphPad Prism 5. Twotailed p-values were calculated using one-way ANOVA followed by the Tukey-Kramer post-test (symbols for p-values shown with a line) or the Dunnett's posttest (comparing to control (mock or wild type), symbols for p-values shown on each column), a Kruskal-Wallis test followed by the Dunn's post-test (symbols for p-values shown with a line), or a paired t-test (comparing two samples, symbols for p-values shown with a line). Symbols represent, *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant (p ≥ 0.05).
The numbers of experimental replicates (n) and statistical information of each figure are as follows. Figure 1a Figure 6b -g, n = 6; Fig. 6h , i, n = 5. Supplementary Fig. 1 : 1a, n = 6; 1b, n = 3; 1c, n = 6; 1d-g, n = 5; 1h, i, n = 6; 1j, n = 3; 1k, n = 6; 1 l, m, n = 4; 1n, o, n = 6. Supplementary Figure 2 : 2a, n: mock 17: + / -Nef 5, + / -Env 5, + / -Vpu 4, + / -Vpr 3, + / -Vif 5; Fig. 2c , n: mock 13; 2b, n = 3; 2c, n = 5, t = 0.3200, df = 4; 2d, n = 5; 2e, n = 4; 2f, g, n = 6; 2 h, n = 5; 2i, n = 5, t = 0.3056, df = 4; 2j, n = 5; 2k, n = 4. Supplementary Fig. 3 : 3b, n = 4; 3c, d, n = 6; 3e, n = 4; 3f, g, n = 4; 3 h, n = 9; 3i, n = 5. Supplementary Fig. 4 : 4a, n: WT = 7, 29/31KE/85YG/ 16EK/12LE/30LE/98EV = 5, 7A2T/21LS/34VE/69TR = 4, F = 0.5085, df = 50; 4b, n: WT = 7, 29/31KE/85YG/16EK/12LE/30LE/98EV = 5, 7A2T/21LS/34VE/69TR = 4, mock = 8; 4c, n: WT = 9, 29/31KE/85YG/16EK/12LE/30LE/98EV = 5, 7A2T/ 21LS/34VE/69TR = 4, mock = 9; 4f, n = 6, t = 0.3934, df = 5; 4g, h, n = 6; 4i, n:
HIV-1 = 8, HIV-2 = 7, SIVmac/SIVagm/SIVcpz/SIVGor = 5, F = 0.2291, df = 34; 4j, k, n: HIV-1/mock = 8, HIV-2 = 7, SIVmac/SIVagm/SIVcpz/SIVGor = 5; 4 l, n: HIV-1 = 17, FIV = 6, HTLVII = 8, EIAV = 9; 4 m, n: HIV-1 = 15, FIV = 6, HTLVII = 8, EIAV = 9, mock = 20; 4n, n: HIV-1 = 9, FIV = 6, HTLVII = 8, EIAV = 9, mock = 13. Supplementary Fig. 5 : 5a, n: Scrambled = 18, MAVS/ STING = 7, RIG-I = 5, MDA5 = 8; 5b, c, n = 7; 5d, n = 6; 5e, n = 8; 5f, n = 3; 5g, n: mock/DMSO = 13, (5Z)-7-Oxozeaenol/BAY11-7082 = 9, Herbimycin A = 7, Calpeptin = 6, Glybenclamide = 4; 5 h, n = 5; 5i, n: DMSO2/(5Z)-7-Oxozeaenol/ BAY11-7082 = 6, Herbimycin A/DMSO1 = 5, F = 0.3910, df = 27. Supplementary  Fig. 6b-d , n = 3.
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